Autonomous drone developer EHang floated at the bottom of its range in an initial public offering that allowed Lung Biotechnology and United Therapeutics to exit.

Financial automation software producer Bill is floating above its range as Fleetcor, Mastercard, Amex and a host of banks all scored exits.

The number of flotations of companies that have previously received corporate backing has been growing over the past years but by the end of 2019 they may register a slight slowdown.

Ant Financial and Nikkei-backed 36Kr has raised just a fifth of its original IPO target and shares took another 10% hit on the first day of trading.

The Celgene and GV-backed small molecule drug developer floated at the bottom of its range, raising less than half the target it set last week.

The Takeda-backed gastrointestinal disease therapy developer has boosted its initial public offering to $209m after its shares rose 23% post-flotation.

Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.

GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.

SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.

The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.